Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts123/v4/7b/09/c8/7b09c896-46f0-4fb3-3335-0cc0308342fb/mza_2858819860156651969.jpg/600x600bb.jpg
The IMID Forum
The Immune-Mediated Inflammatory Disease Forum
381 episodes
1 day ago
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Show more...
Education
RSS
All content for The IMID Forum is the property of The Immune-Mediated Inflammatory Disease Forum and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Show more...
Education
https://i1.sndcdn.com/artworks-Hw7y5a7eTNAzpBbH-2RdJoQ-t3000x3000.png
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
The IMID Forum
14 minutes 37 seconds
1 day ago
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
The IMID Forum
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.